Global Cell Therapy Market (2020 to 2025) - Growth, Trends, and Forecast - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Cell Therapy Market- Growth, Trends, and Forecast (2020 - 2025)" report has been added to ResearchAndMarkets.com's offering.

The cell therapy market will show rapid growth due to the increasing prevalence of chronic conditions, rising adoption of regenerative medicine and rise in the number of clinical studies pertaining to the development of cellular therapies.

Chronic diseases and conditions are on the rise worldwide. According to the World Health Organization, chronic disease prevalence is expected to rise by 57% by the year 2020. The emerging markets will be hardest hit, as population growth is anticipated be most significant in developing nations. Increased demand for healthcare systems due to chronic disease has thus become a major concern. Healthcare expenditures greatly increase, with each additional chronic condition with greater specialist physician access, emergency department presentations and hospital admissions.

Therefore the increasing prevalence of chronic conditions, government assistance and numerous companies investing heavily in stem cell therapy research and development will help to stimulate the industry growth. The proven effectiveness of cell therapy products coupled with increasingly favorable guidelines pertaining to cell therapy research and manufacturing should positively impact industry growth.

Companies Mentioned

• Anterogen Co., Ltd.
• Tego Science
• Chiesi Farmaceutici S.p.A.
• Corestem Inc.
• Pharmicell Co Ltd.
• Fibrocell Technologies Inc
• Nipro Corp
• MEDIPOST
• TiGenix (Takeda Pharmaceuticals)
• Stempeutics Research Pvt. Ltd.

Key Market Trends

Allogeneic Therapies Segment Accounted for the Largest Share in the Cell Therapy Market

Allogeneic therapies rely on a single source of cells to treat many patients. They increase the risk of eliciting an immune response within a patient, and immunosuppressive therapies are sometimes administered in combination with allogeneic products. Therefore there is an increasing inclination of physicians towards therapeutic use of allogeneic therapies coupled with rising awareness about the use of cord cells and tissues across various therapeutic areas is driving revenue generation.

Furthermore, the presence of a substantial number of approved products for clinical use has led to the large revenue share of this segment.

North America is Leading the Cell Therapy Market

North America is estimated to retain the largest share of the market due to the presence of strong regulatory framework in order to promote cellular therapy development, the existence of industry big shots, and high cost of therapies in the U.S. There is also the presence of leading universities that supports the research activities in the U.S. is one of the key factor driving the market for cell therapy in North America.

The Asia Pacific market is also increasing at a rapid rate due to the availability of therapies at lower prices coupled with growing awareness among the healthcare entities and patients pertaining the potential of these therapies in chronic disease management.

Key Topics Covered:

1 INTRODUCTION

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

4.1 Market Overview

4.2 Market Drivers

4.2.1 Increasing Prevalence of Chronic Conditions

4.2.2 Rising Adoption of Regenerative Medicine

4.2.3 Rise in Number of Clinical Studies Pertaining to the Development of Cellular Therapies

4.3 Market Restraints

4.3.1 High Cost of Therapies

4.4 Porter's Five Force Analysis

4.4.1 Threat of New Entrants

4.4.2 Bargaining Power of Buyers/Consumers

4.4.3 Bargaining Power of Suppliers

4.4.4 Threat of Substitute Products

4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

5.1 By Type

5.1.1 Autologous

5.1.2 Allogeneic

5.2 By Therapy

5.2.1 Mesenchymal Stem Cell Therapy

5.2.2 Fibroblast Cell Therapy

5.2.3 Hematopoietic Stem Cell Therapy

5.2.4 Other Therapies

5.3 By Application

5.3.1 Musculoskeletal

5.3.2 Malignancies

5.3.3 Cardiovascular

5.3.4 Dermatology & Wounds

5.3.5 Other Applications

5.4 Geography

5.4.1 North America

5.4.1.1 United States

5.4.1.2 Canada

5.4.1.3 Mexico

5.4.2 Europe

5.4.2.1 Germany

5.4.2.2 United Kingdom

5.4.2.3 France

5.4.2.4 Italy

5.4.2.5 Spain

5.4.2.6 Rest of Europe

5.4.3 Asia-Pacific

5.4.3.1 China

5.4.3.2 Japan

5.4.3.3 India

5.4.3.4 Australia

5.4.3.5 South Korea

5.4.3.6 Rest of Asia-Pacific

5.4.4 Middle-East and Africa

5.4.4.1 GCC

5.4.4.2 South Africa

5.4.4.3 Rest of Middle East and Africa

5.4.5 South America

5.4.5.1 Brazil

5.4.5.2 Argentina

5.4.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

6.1 Company Profiles

6.1.1 Anterogen Co., Ltd.

6.1.2 Tego Science

6.1.3 Chiesi Farmaceutici S.p.A.

6.1.4 Corestem Inc.

6.1.5 Pharmicell Co Ltd.

6.1.6 Fibrocell Technologies Inc

6.1.7 Nipro Corp

6.1.8 MEDIPOST

6.1.9 TiGenix (Takeda Pharmaceuticals)

6.1.10 Stempeutics Research Pvt. Ltd.

7 MARKET OPPORTUNITIES AND FUTURE TRENDS

For more information about this report visit https://www.researchandmarkets.com/r/9qtcg2